drugset / Trial / NCT00254293
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-05
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abatacept | Other / unclassified | 75 mg | Intravenous |
| Comparator | Abatacept | Other / unclassified | 125 mg | Intravenous |
| Comparator | Abatacept | Other / unclassified | 200 mg | Intravenous |